Why the study?
While SGLT-2 inhibitors improve strain parameters and lower AF recurrence in type 2 diabetes, their impact on LA mechanical functions and recurrence in non-diabetic patients after CB-2 ablation for PAF was unknown.
Does dapagliflozin improve left atrial mechanical functions and reduce AF recurrence in non-diabetic patients with preserved EF after cryoballoon ablation for paroxysmal atrial fibrillation?
Population
80 consecutive non-diabetic preserved EF patients with PAF undergoing CB-2 ablation
Comparison
Dapagliflozin initiated post-procedure vs no dapagliflozin
Design
Cohort study
Follow-up
3 months
Key result
Dapagliflozin significantly improved left atrial compliance (LAscd -18.5% vs -14.4%, p<0.001) at 3 months in non-diabetic patients following cryoballoon ablation for paroxysmal atrial fibrillation.
Authors
Loading...
SGLT2 inhibitors were associated with improved early LA function and lower AF recurrence post-cryoballoon ablation; leaves open whether this extends beyond small observational cohorts.
Cohort (n=80)
Does dapagliflozin improve left atrial mechanical functions and reduce AF recurrence in non-diabetic patients with preserved EF after cryoballoon ablation for paroxysmal atrial fibrillation?
p-value: p=<0.001
Dapagliflozin may improve left atrial mechanical function and compliance in the early post-ablation period for non-diabetic patients with paroxysmal atrial fibrillation.
Soysal et al. (2025) conducted a cohort in Paroxysmal atrial fibrillation (n=80). Dapagliflozin vs. Not using dapagliflozin was evaluated on Left atrial compliance (LAscd) (p=<0.001). Dapagliflozin significantly improved left atrial compliance (LAscd -18.5% vs -14.4%, p<0.001) at 3 months in non-diabetic patients following cryoballoon ablation for paroxysmal atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: